Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry balks at melamine guidance

This article was originally published in The Tan Sheet

Executive Summary

A coalition of pharma industry groups, including the Consumer Healthcare Products Association and the Pharmaceutical Research and Manufacturers of America, requests FDA withdraw its final 1guidance on testing for melamine contamination in pharmaceutical products, which the agency issued in August. In a Sept. 9 2letter, the Coalition for the Monitoring of Melamine Adulteration says given the lack of "acute risk" from melamine in their products, FDA should reissue the guidance in draft form with a Q&A document and allow for a comment period. The coalition recommends FDA address supply chain integrity, rather than focus on specific adulterants. Industry also asks FDA to be more flexible about testing methods and eliminate the word "requirements." FDA acknowledged it is not aware of any melamine-contaminated drugs (3"The Tan Sheet" Aug. 10, 2009, In Brief)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel